Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 9, 2024Nuklearmedizin - NuclearMedicine

FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)

View Full Paper
Ask AI
Bookmark
Share

Authors

CWChristoph‐Ferdinand WielenbergJFJohannes FostitschCVChristian Volz

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wielenberg et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677b0ehttps://doi.org/10.1055/a-2283-8417
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014 · 5,731 citations
  2. 2Fluorine-18-fluorodeoxyglucose uptake of bone marrow on PET/CT can predict prognosis in patients with colorectal cancer after curative surgical resection2017 · 28 citations
  3. 3Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy2023 · 25 citations
  4. 4Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy2021 · 28 citations
  5. 5Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy2022 · 46 citations